Last updated on March 2019

Human Fibrinogen Concentrate in Pediatric Cardiac Surgery


Brief description of study

The goal of the study is to determine whether the use of Human Fibrinogen Concentrate (RiaSTAP) will decrease the need for component blood therapy in neonates and infants undergoing cardiopulmonary bypass.

Detailed Study Description

The goal of the study is to determine whether the use of Human Fibrinogen Concentrate (RiaSTAP) will decrease the need for component blood therapy in neonates and infants undergoing cardiopulmonary bypass. RiaSTAP will be administered after termination of Cardiopulmonary Bypass (CPB) at a dose of 70 mg/kg, in a prospective, randomized, controlled study. We hypothesize that the administration of RiaSTAP in this manner will reduce peri-operative bleeding and transfusion requirements.

Clinical Study Identifier: NCT02822599

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.